• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

    5/6/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XTNT alert in real time by email

    BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025.

    Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results.

    Conference Details:

    Conference Date: Monday, May 12, 2025

    Conference Time: 4:30 PM ET

    Conference dial-in: 888-506-0062

    International dial-in: 973-528-0011

    Passcode: 828748

    Conference Call Name: Xtant Medical Q1 2025 Financial Results

    Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/52428

    Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor Info."

    About Xtant Medical Holdings, Inc.

    Xtant Medical's mission of "honoring the gift of donation so that our patients can live as full and complete a life as possible" is the driving force behind our company. Xtant Medical Holdings, Inc. ( www.xtantmedical.com ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

    The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States , and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

    Cision View original content:https://www.prnewswire.com/news-releases/xtant-medical-to-issue-first-quarter-2025-financial-results-on-may-12-2025-302447175.html

    SOURCE Xtant Medical Holdings, Inc.

    Get the next $XTNT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XTNT

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    More analyst ratings

    $XTNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xtant Medical Reports Second Quarter 2025 Financial Results

    Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue

    8/12/25 7:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Attend the CG 45th Annual Growth Conference

    BELGRADE, Mont., Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference: Event: CG 45th Annual Growth ConferenceDate: August 12, 2025 at 3:30pm ETLocation: Boston, MAFormat: 1x1 Meetings & Presentation For more information, please visit:https://wsw.com/webcast/canaccord108/xtnt/2576418  About Xtant Medical Holdings, Inc. X

    8/6/25 4:01:00 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025

    BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the start of trading on Tuesday, August 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, August 12

    8/5/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Brandt Kevin D bought $49,837 worth of shares (41,670 units at $1.20), increasing direct ownership by 5% to 815,860 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    11/17/23 4:42:41 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Browne Sean E covered exercise/tax liability with 10,605 shares, decreasing direct ownership by 0.48% to 2,180,337 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    8/19/25 4:45:36 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO Neils Scott C covered exercise/tax liability with 34,131 shares, decreasing direct ownership by 5% to 588,174 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    8/19/25 4:40:28 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Lipschultz Tyler

    3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    8/8/25 4:20:04 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    SEC Filings

    View All

    SEC Form 10-Q filed by Xtant Medical Holdings Inc.

    10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    8/12/25 8:50:26 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    8/12/25 7:51:29 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    8/8/25 4:15:58 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Xtant Medical with a new price target

    BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

    12/5/23 8:12:02 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

    BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va

    5/18/23 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer

    BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio

    1/9/23 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Financials

    Live finance-specific insights

    View All

    Xtant Medical Reports Second Quarter 2025 Financial Results

    Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue

    8/12/25 7:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025

    BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the start of trading on Tuesday, August 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, August 12

    8/5/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

    Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont., July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilizatio

    7/8/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Xtant Medical Holdings Inc.

    SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    9/10/24 4:12:57 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Xtant Medical Holdings Inc. (Amendment)

    SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    2/13/24 5:10:19 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

    SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    8/3/23 4:59:55 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care